Intraperitoneal chemotherapy: Principles and results of clinical trials

  • Maurie Markman
  • Stephen B. Howell
Part of the Cancer Treatment and Research book series (CTAR, volume 36)


While the intraperitoneal administration of chemotherapeutic agents for their cytotoxic rather than sclerosing properties is not a new idea [1,2], recent modelling studies, suggesting a pharmacokinetic rationale for this method of drug delivery to tumors principally confined to the peritoneal cavity, has renewed interest in this idea [3]. In this review the basic principles of intraperitoneal chemotherapy will be presented along with a discussion of the theoretical and practical problems associated with the technique. Finally, a summary of recent single agent and combination intraperitoneal chemotherapy trials will be presented as well as a brief discussion of other innovative approaches utilizing the intraperitoneal route.


Peritoneal Cavity Ovarian Carcinoma Malignant Mesothelioma Intraperitoneal Chemotherapy Proc ASCO 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Weisberger AS, Levine B, and Storaasli JP: Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. JAMA 159:1704–1707, 1955.Google Scholar
  2. 2.
    Green TH: Hemisulfer mustard in the palliation of patients with metastatic ovarian carcinoma. Obstet Gynecol 13:383–393, 1959.PubMedGoogle Scholar
  3. 3.
    Dedrick RL, Myers CE, Bungay PM, and DeVita VT Jr: Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62:1–9, 1978.PubMedGoogle Scholar
  4. 4.
    Kraft AR, Tompkins RK, and Jesseph JE: Peritoneal electrolyte absorption: Analysis of portal, systemic venous, and lymphatic transport. Surgery 64:148–153, 1968.PubMedGoogle Scholar
  5. 5.
    Lukas G, Brindle S, and Greengard P: The route of absorption of intraperitoneally administered compounds. J Pharmacol Exp Ther 178:562–566, 1971.PubMedGoogle Scholar
  6. 6.
    Lockard RD, Hamilton GF, and Fyfe FW: Anatomy of the Human Body. Philadelphia: JB Lippincott Company, 1960.Google Scholar
  7. 7.
    Romanes GB (ed): Cunningham’s Textbook of Anatomy. London: Oxford University, 1964.Google Scholar
  8. 8.
    Torres IJ, Litterst CL, and Guarino AM: Transport of model compounds across the peritoneal membrane in the rat. Pharmacology 17:330–340, 1978.PubMedGoogle Scholar
  9. 9.
    Litterst CL, Torres IJ, Arnold S, et al: Absorption of antineoplastic drugs following large-volume IP administration to rats. Cancer Treat Rep 66:147–155, 1982.PubMedGoogle Scholar
  10. 10.
    Speyer JL, Sugarbaker PH, Collins JM, Dedrick RL, Klecker RW, and Myers CE: Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res 41:1916–1922, 1981.PubMedGoogle Scholar
  11. 11.
    Howell SB, Chu BCF, Wung WE, Metha BM, and Mendelsohn J: Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions. J Clin Invest 67:1161–1170, 1981.PubMedGoogle Scholar
  12. 12.
    Jones RB, Collins JM, Myers CE, et al: High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer. Cancer Res 41:55–59, 1981.PubMedGoogle Scholar
  13. 13.
    Howell SB, Pfeifle CE, Wung WE, et al: Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 97:845–851, 1982.PubMedGoogle Scholar
  14. 14.
    Howell SB, Pfeifle CE, Wung WE, and Olshen RA: Intraperitoneal cisplatin with systemic thiosulfate protection. Cancer Res 43:1426–1431, 1983.PubMedGoogle Scholar
  15. 15.
    West GW, Weichselbaum R, and Little JB: Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy. Cancer Res 40:3665–3668, 1980.PubMedGoogle Scholar
  16. 16.
    Durand RE: Flow cytometry studies of intracellular adriamycin in multicell spheroids in vitro. Cancer Res. 41:3495–3498, 1981.PubMedGoogle Scholar
  17. 17.
    Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE, and Young RC: Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Can Res 39:3209–3214, 1979.Google Scholar
  18. 18.
    Ozols RF, Grotzinger KR, Fisher RI, Myers CE, and Young RC: Kinetic characterization and response to chemotherapy in a transplantable murine ovarian cancer. Cancer Res 39:3202–3208, 1979.PubMedGoogle Scholar
  19. 19.
    Ozols RF, Locker GY, Doroshow JH, et al: Chemotherapy for murine ovarian cancer: A rationale for IP therapy with adriamycin. Cancer Treat Rep 63:269–273, 1979.PubMedGoogle Scholar
  20. 20.
    Schwartz HS: A fluorometric assay for daunomycin and adriamycin in animal tissues. Biochem Med 7:396–404, 1973.PubMedGoogle Scholar
  21. 21.
    Donelli MG, Martini A, Colombo T, Bossi A, and Garattini S: Heart levels of adriamycin in normal and tumor-bearing mice. Eur J Cancer 12:913–923, 1976.PubMedGoogle Scholar
  22. 22.
    Tully TE, Goldberg ME, and Locken MK: The use of 99 Tc-sulfur colloid to assess the distribution of 32P chromic phosphate. J Nucl Med 15:190–191, 1974.Google Scholar
  23. 23.
    Taylor A, Baily NA, Halpern SE, and Ashburn WL: Loculation as a contraindication to intracavitary 32P chromic phosphate therapy. J Nucl Med 16:318–319, 1975.PubMedGoogle Scholar
  24. 24.
    Vider M, Deland FM, and Maruyama Y: Loculation as a contraindication to intracavitary 32P chromic phosphate therapy. J Nucl Med 17:150–151, 1976.PubMedGoogle Scholar
  25. 25.
    Rosenshein N, Blake D, Mclntyre PA, et al: The effect of volume on the distribution of substances instilled into the peritoneal cavity. Gynecol Oncol 6:106–110, 1978.PubMedGoogle Scholar
  26. 26.
    Dunnick NR, Jones RB, Doppman JL, Speyer J, and Myers CE: Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamics. AJR 133:221–223, 1979.PubMedGoogle Scholar
  27. 27.
    Kaplan RA, Markman, M, Lucas WE, Pfeifle C, and Howell SB: Infectious peritonitis in patients receiving intraperitoneal chemotherapy. Am J Med 78:49–53, 1985.PubMedGoogle Scholar
  28. 28.
    Myers C: The use of intraperitoneal chemotherapy in the treatment of ovarian cancer. Semin Oncol 11:275–284, 1984.PubMedGoogle Scholar
  29. 29.
    Jenkins J, Sugarbaker PH, Gianola FJ, and Myers CE: Technical considerations in the use of intraperitoneal chemotherapy administered by Tenckhoff catheter. Surg Gynecol Obstet 154:858–864, 1982.PubMedGoogle Scholar
  30. 30.
    Lucas WE: Surgical principles of intraperitoneal access and therapy. In: Intra-arterial and Intracavitary Chemotherapy, SB Howell (ed). Boston: Martinus Nijhoff, p 53–60, 1984.Google Scholar
  31. 31.
    Pfeifle CE, Howell SB, Markman M, and Lucas WE: Totally implantable system for peritoneal access. J Clin Oncol 2:1277–1280, 1984.PubMedGoogle Scholar
  32. 32.
    King ME, Pfeifle CE, and Howell SB: Intraperitoneal cytosine arabinoside in ovarian carcinoma. J Clin Oncol 2:662–669, 1984.PubMedGoogle Scholar
  33. 33.
    Gloor HJ, Nichols WK, Sorkin MI, et al: Peritoneal access and related complications in continuous ambulatory peritoneal dialysis. Am J Med 74:593–598, 1983.PubMedGoogle Scholar
  34. 34.
    Rubin J, Rogers WA, Taylor HM, et al: Peritonitis during continuous ambulatory dialysis. Ann Intern Med 92:7–13, 1980.PubMedGoogle Scholar
  35. 35.
    Krothapalli RK, Senekjian HO, and Ayus JC: Efficacy of intravenous vancomycin in the treatment of gram-positive peritonitis in long-term peritoneal dialysis. Am J Med 75:345–348, 1983.PubMedGoogle Scholar
  36. 36.
    Knight KR, Polak A, Crump J, and Maskell R: Laboratory diagnosis and oral treatment of CAPD peritonitis. Lancet 2:1301–1304, 1982.PubMedGoogle Scholar
  37. 37.
    Ozols RF, Young RC, Speyer JL, et al: Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res 42:4265–4269, 1982.PubMedGoogle Scholar
  38. 38.
    Markman M, Cleary S, Howell SB, and Lucas WE: Complications of extensive adhesion formation following intraperitoneal chemotherapy. Surg Gynecol Oncol (in press), 1985.Google Scholar
  39. 39.
    Deserga GS, and Holtz GD: Cause and prevention of postsurgical pelvic adhesions. In: Advances in Clinical Obstetrics and Gynecology, HS Osotsky (ed). Baltimore: Williams and Wilkins Co, p 277–289, 1982.Google Scholar
  40. 40.
    Stangel JJ, Nisbet JD, and Settles H: Formation and prevention of postoperative abdominal adhesions. J Repro Med 29:143–156, 1984.Google Scholar
  41. 41.
    Tobias JS and Griffiths CT: Management of ovarian carcinoma: Current concepts and future prospects. N Engl J Med 294:877–882, 1976.PubMedGoogle Scholar
  42. 42.
    Roboz J, Jacobs AJ, Holland JF, Deppe G, and Cohen CJ: Intraperitoneal infusion of doxorubicin in the treatment of gynecologic carcinomas. Med Pediat Oncol 9:245–250, 1981.Google Scholar
  43. 43.
    Alberts DS, Mackel C, and Peng YM: Comparative activity of anticancer drugs used in high dose by the intraperitoneal route for the treatment of advanced ovarian cancer. Proc ASCO 4:36, 1985.Google Scholar
  44. 44.
    Suhrland LG and Weisberger AS: Intracavitary 5-fluorouracil in malignant effusions. Arch Intern Med 116:431–433, 1965.PubMedGoogle Scholar
  45. 45.
    Clarkson B: Relationship between cell type, glucose concentration, and response to treatment in neoplastic effusions. Cancer 17:914–928, 1964.PubMedGoogle Scholar
  46. 46.
    Clarkson B, O’Connor A, Winston L, and Hutchison D: The physiologic disposition of 5-fluorouracil and 5-fluoro-2’-deoxyuridine in man. Clin Pharmacol Ther 5:581–610, 1964.PubMedGoogle Scholar
  47. 47.
    Speyer JL, Collins JM, Dedrick RL, et al: Phase I pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res 40:567–572, 1980.PubMedGoogle Scholar
  48. 48.
    Demicheli R, Jirillo A, Bonciarelli G, et al: Pharmacological data and technical feasibility of intraperitoneal 5-fluorouracil administration. Tumori 68:437–441, 1982.PubMedGoogle Scholar
  49. 49.
    Gyves JW, Ensminger WD, Stetson P, et al: Constant intraperitoneal 5-fluorouracil infusion through a totally implanted system. Clin Pharmacol Ther 35:83–89, 1984.PubMedGoogle Scholar
  50. 50.
    Ozols RF, Speyer JL, Jenkins J, and Myers CE: Phase II trial of 5-FU administered IP to patients with refractory ovarian cancer. Cancer Treat Rep 68:1229–1232, 1984.PubMedGoogle Scholar
  51. 51.
    Jones RB, Myers CE, Guarino AM, Dedrick RL, Hubbard SM, and DeVita VT: High volume intraperitoneal chemotherapy (’belly bath’) for ovarian cancer. Cancer Chemother Pharmacol 1:161–166, 1978.PubMedGoogle Scholar
  52. 52.
    Speyer JL and Myers CE: The use of peritoneal dialysis for delivery of chemotherapy to intraperitoneal malignancies. Recent Results Cancer Res 74:264–269, 1980.PubMedGoogle Scholar
  53. 53.
    Katz ME, Schwartz PE, Kapp DS, and Luikart S: Epithelial carcinoma of the ovary: Current strategies. Ann Intern Med 95:98–111, 1981.PubMedGoogle Scholar
  54. 54.
    Casper ES, Kelsen DP, Alcock NW, and Lewis JL: IP cisplatin in patients with malignant ascites: Pharmacokinetic evaluation and comparison with the IV route. Cancer Treat Rep 67:235–238, 1983.PubMedGoogle Scholar
  55. 55.
    Pretorious RG, Hacker NF, Berek JS, et al: Pharmacokinetics of IP cisplatin in refractory ovarian carcinoma. Cancer Treat Rep 67:1085–1092, 1983.Google Scholar
  56. 56.
    Chen KK and Rose CL: Nitrite and thiosulfate therapy in cyanide poisoning. JAMA 149:113–119, 1952.Google Scholar
  57. 57.
    Gilman A, Philips FS, and Koelle ES: The renal clearance of thiosulfate with observations on its volume of distribution. Am J Physiol 146:348–357, 1946.PubMedGoogle Scholar
  58. 58.
    Howell SB and Taetle R: Effect of sodium thiosulfate on cisdichlorodiammineplatinum(II) toxicity and antitumor activity in L1210 leukemia. Cancer Treat Rep 64:611–616, 1970.Google Scholar
  59. 59.
    Iwamoto Y, Kawano T, Uozumi J, Aoki K, and Baba T: ’Two-route chemotherapy’ using high-dose IP cisplatin and IV sodium thiosulfate, its antidote, for peritoneally disseminated cancer in mice. Cancer Treat Rep 68:1367–1373, 1984.PubMedGoogle Scholar
  60. 60.
    Belt RJ, Himmelstein KJ, Patton TF, Bannister SJ, Sternson LA, and Repta AJ: Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum(II). Cancer Treat Rep 63:1515–1521, 1979.PubMedGoogle Scholar
  61. 61.
    Pfeifle CE, Howell SB, Felthouse RD, Woliver TBS, and Markman M: High-dose cisplatin with sodium thiosulfate. J Clin Oncol 3:237–244, 1985.PubMedGoogle Scholar
  62. 62.
    Shea M, Koziol JA, and Howell SB: Kinetics of sodium thiosulfate, a cisplatin neutralizer. Clin Pharmacol Ther 35:419–425, 1984.PubMedGoogle Scholar
  63. 63.
    Markman M, Clearly S, and Howell SB: Nephrotoxicity of high-dose intracavitary cisplatin with intravenous thiosulfate protection. Eur J Cancer Clin Oncol 21:1015–1018, 1985.PubMedGoogle Scholar
  64. 64.
    Ozols RF, Corden BJ, Jacob J, Wesley MN, Ostchega Y, and Young RC: High-dose cisplatin in hypertonic saline. Ann Intern Med 100:19–24, 1984.PubMedGoogle Scholar
  65. 65.
    Markman M, Cleary S, Pfeifle CE, and Howell SB: High-dose intra-cavitary cisplatin with intravenous thiosulfate: Low incidence of serious neurotoxicity. Cancer 56:2364–2368, 1985.PubMedGoogle Scholar
  66. 66.
    Clark AW, Parhad I, Griffin JW, and Price DL: Neurotoxicity of cisplatinum: Pathology of the central peripheral nervous systems. Neurology 30:429, 1980.Google Scholar
  67. 67.
    McVie JG, Ten Bokkel Huinink WW, Aartsen E, Simonetti G, Dubbelman R, and Franklin H: Intraperitoneal chemotherapy in minimal residual ovarian cancer with cisplatin and IV sodium thiosulfate protection. Proc ASCO 4:125, 1985.Google Scholar
  68. 68.
    Pfeifle CE, Howell SB, and Markman: Intracavitary cisplatin chemotherapy for mesothelioma. Cancer Treat Rep 69:205–207, 1985.PubMedGoogle Scholar
  69. 69.
    Antman KH, Blue RH, Greenberger JS, Flowerdew G, Skarin AT, and Canellos GP: Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med 68:356–362, 1980.PubMedGoogle Scholar
  70. 70.
    Aisner J and Wiernik PH: Chemotherapy in the treatment of malignant mesothelioma. Semin Oncol 8:335–343, 1981.PubMedGoogle Scholar
  71. 71.
    Mintzer DM, Kelsen D, Frimmer D, Heelan R, and Gralla R: Phase II trial of high-dose cisplatin in patients with malignant mesothelioma. Cancer Treat Rep 69:711–712, 1985.PubMedGoogle Scholar
  72. 72.
    Ho DH and Frei E 3rd: Clinical pharmacology of 1-beta-D-arabinofuranosyl cytosine. Clin Pharmacol Ther 12:944–954, 1971.Google Scholar
  73. 73.
    Van Prooijen R, Van der Kleijn E, and Haanen C: Pharmacokinetics of cytosine arabino-side in acute myeloid leukemia. Clin Pharmacol Ther 21:744–750, 1977.PubMedGoogle Scholar
  74. 74.
    Bodey GP, Freireich EJ, Monto RW, and Hewlett JS: Cytosine arabinoside (NSC-63878) therapy for acute leukemia in adults. Cancer Chemo Rep 53:59–66, 1969.Google Scholar
  75. 75.
    Ellison RR, Holland JF, Weil M, et al: Arabinosyl cytosine: A useful agent in the treatment of acute leukemia in adults. Blood 32:507–523, 1968.PubMedGoogle Scholar
  76. 76.
    Wasserman TH, Comis RL, Goldsmith M, et al: Tabular analysis of the clinical chemotherapy of solid tumors. Cancer Chemother Rep 6:399–419, 1975.Google Scholar
  77. 77.
    Markman M: The intracavitary administration of cytarabine to patients with nonhemato-poietic malignancies: Pharmacologic rationale and results of clinical trials. Semin Oncol 12(2) Suppl 3:177–183, 1985.PubMedGoogle Scholar
  78. 78.
    Holcenberg J, Anderson T, Ritch P, et al: Intraperitoneal chemotherapy with melphalan plus glutaminase. Cancer Res 43:1381–1388, 1983.PubMedGoogle Scholar
  79. 79.
    Howell SB, Pfeifle CE, and Olshen RA: Intraperitoneal chemotherapy with melphalan. Ann Intern Med 101:14–18, 1984.PubMedGoogle Scholar
  80. 80.
    Gyves J, Ensminger W, Niederhuber J, et al: Phase I study of intraperitoneal 5 day continuous 5-FU infusion and bolus mitomycin C, Proc ASCO 1:15, 1982.Google Scholar
  81. 81.
    Adams SC, Patt YZ, and Rosenblum MG: Pharmacokinetics of mitomycin C following intraperitoneal administration of mitomycin C and floxuridine for peritoneal carcinomatosis. Proc AACR 25:361, 1984.Google Scholar
  82. 82.
    Allen LM, Tejada F, Okonmah AD, and Nordqvist S: Combination chemotherapy of the epipodophyllotoxin derivatives, teniposide and etoposide: A pharmacodynamic rationale? Cancer Chemother Pharmacol 7:151–156, 1982.PubMedGoogle Scholar
  83. 83.
    Jones JM, Olman EA, Egorin MJ, and Aisner J: A case report and description of the pharmacokinetic behavior of intrapleurally instilled etoposide. Cancer Chemother Pharmacol 14:172–174, 1985.PubMedGoogle Scholar
  84. 84.
    Stahelin H: Delayed toxicity of epipodophyllotoxin derivatives (VM 26 and VP 16–213), due to a local effect. Europ J Cancer 12:925–931, 1976.Google Scholar
  85. 85.
    Panasci LC, Skalski V, St-Germain J, Lazarus P, Shinder M, and Margolese R: Pharmacology and toxicity of IP streptozotocin in ovarian cancer: A case report. Cancer Treat Rep 66:1595–1596, 1982.Google Scholar
  86. 86.
    Goldie JH and Coldman AJ: A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727–1733, 1979.PubMedGoogle Scholar
  87. 87.
    Goldie JH, Coldman AJ, and Gudauskas GA: Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 66:439–449, 1982.PubMedGoogle Scholar
  88. 88.
    Alberts DS, Chen HSG, Chang SY, and Peng YM: The disposition of intraperitoneal bleomycin, melphalan, and vinblastine in cancer patients. Recent Results Cancer Res 74:293–299, 1980.PubMedGoogle Scholar
  89. 89.
    Bergerat J-P, Drewinko B, Corry P, Barlogie B, and Ho DH: Synergistic lethal effect of cis-dichlorodiammineplatinum and 1-beta-D-arabinofuranosylcytosine. Cancer Res 41:25 - 30, 1981.PubMedGoogle Scholar
  90. 90.
    Einhorn LH, Willams SD, and Loehrer PJ: Combination chemotherapy with platinum plus 5-FU in metastatic colorectal carcinoma. Proc ASCO 3:133, 1984.Google Scholar
  91. 91.
    Einhorn LH and Donohue J: Cisdiamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87:293–298, 1977.PubMedGoogle Scholar
  92. 92.
    Stoter G, Vendrik CPJ, Struyvenberg A, et al: Combination chemotherapy with cisdiammine-dichloroplatinum, vinblastine, and bleomycin in advanced testicular nonseminoma. Lancet 1:941–945, 1979.PubMedGoogle Scholar
  93. 93.
    Mascharak PK, Sugiura Y, Kuwahara J, Suzuki T, and Lippard SJ: Alteration and activation of sequence-specific cleavage of DNA by bleomycin in the presence of the antitumor drug cisdiamminedichloroplatinum(II). Proc Natl Acad Sci 80:6795–6798, 1983.PubMedGoogle Scholar
  94. 94.
    Alberts DS, Chen HSG, Mayersohn M, Perrier D, Moon TE, and Gross JF: Bleomycin pharmacokinetics in man. II. Intracavitary administration. Cancer Chemother Pharmacol 2:127–132, 1979.PubMedGoogle Scholar
  95. 95.
    Alberts DS, Salmon SE, Chen HSG, et al: In vitro clonogenic assay for predicting response of ovarian cancer to chemotherapy. Lancet 2:340–342, 1980.PubMedGoogle Scholar
  96. 96.
    Blackledge G, Lawton F, Buckley H, and Crowther D: Phase II evaluation of bleomycin in patients with advanced epithelial ovarian cancer. Cancer Treat Rep 68:549–550, 1984.PubMedGoogle Scholar
  97. 97.
    Williams SD and Einhorn LH: Etoposide salvage therapy for refractory germ cell tumors: An update. Cancer Treat Rev 9(suppl A):67–71, 1982.PubMedGoogle Scholar
  98. 98.
    Evans WK, Osoba D, Feld R, Shepherd FA, Bazos MJ, and DeBoer: Etoposide (VP-16) and cisplatin: An effective treatment for relapse in small-cell lung cancer. J Clin Oncol 3:65–71, 1985.PubMedGoogle Scholar
  99. 99.
    O’Dwyer PJ, Leyland-Jones B, Alonso MT, Marsoni S, and Wittes RE: Etoposide (VP-16–213), current status of an active anticancer drug. N Engl J Med 312:692–700, 1985.PubMedGoogle Scholar
  100. 100.
    Canetta R, Hilgard P, Florentine S, Bedogni P, and Lenaz L: Current development of podophyllotoxins. Cancer Chemother Pharmacol 7:93–98, 1982.PubMedGoogle Scholar
  101. 101.
    Schabel FM, Trader MW, Laster WR, Corbett TH, and Griswold DP: Cis-dichlorodiammineplatinum(II): Combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 63:1459–1473, 1979.PubMedGoogle Scholar
  102. 102.
    Markman M, Howell SB, Lucas WE, Pfeifle CE, and Green MR: Combination intraperitoneal chemotherapy with cisplatin, cytarabine, and doxorubicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavity. J Clin Oncol 2:1321–1326, 1984.PubMedGoogle Scholar
  103. 103.
    Markman M, Howell SB, Cleary S, and Lucas WE: Intraperitoneal chemotherapy with high dose cisplatin and cytarabine for refractory ovarian carcinoma and other malignancies principally involving the peritoneal cavity. J Clin Oncol 3:925–931, 1985.PubMedGoogle Scholar
  104. 104.
    Markman M, Cleary S, Lucas WE, Weiss R and Howell SB: Ip chemotherapy employing a regimen of cisplatin, cytarabine, and bleomycin. Cancer Treat Rep 70:755–760, 1986.PubMedGoogle Scholar
  105. 105.
    Spratt JS, Adcock RA, Muskovin M, Sherrill W, and McKeown J: Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 40:256–260, 1980.PubMedGoogle Scholar
  106. 106.
    Gianni L, Jenkins JF, Greene RF, Lichter AS, Myers CE, and Collins JM. Pharmacokinetics of the hypoxic radiosensitizers misonidazole and demethylmisonidazole after intraperitoneal administration in humans. Cancer Res 43:913–916, 1983.PubMedGoogle Scholar
  107. 107.
    Stratford IJ, Adams GE, Horsman MR, et al: The interaction of misonidazole with radiation, chemotherapeutic agents, or heat: A preliminary report. Cancer Clin Trials 3:231–236, 1980.PubMedGoogle Scholar
  108. 108.
    Bast RC, Berek JS, Obrist R, et al: Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum. Cancer Res 43:1395–1401, 1983.PubMedGoogle Scholar
  109. 109.
    Berek J, Knapp R, Hacker N, et al: Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum. Proc ASCO 3:173, 1984.Google Scholar
  110. 110.
    Torisu M, Katano M, Kimura Y, Itoh H, and Takesue M: New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival. Surgery 93:357–364, 1983.PubMedGoogle Scholar
  111. 111.
    Katano M and Torisu M: New approach to management of ascites with a streptococcal preparation, OK-432. II. Intraperitoneal inflammatory cell-mediated tumor cell destruction. Surgery 93:365–373, 1983.PubMedGoogle Scholar
  112. 112.
    Berek J, Hacker N, Lichtenstein A, et al: Intraperitoneal immunotherapy of human ovarian carcinoma with recombinant interferon: A Phase I toxicity/immunopharmacology study. Proc ASCO 4:218, 1985.Google Scholar
  113. 113.
    Rambaldi A, Introna M, Colotta F, et al: Intraperitoneal administration of interferon-B in ovarian cancer patients. Cancer 56:294–301, 1985.PubMedGoogle Scholar
  114. 114.
    Tochner Z, Mitchell JB, Harrington FS, Smith P, Russo DT, and Russo A: Treatment of murine intraperitoneal ovarian ascitic tumor with hematoporphyrin derivative and laser light. Cancer Res 45:2983–2987, 1985.PubMedGoogle Scholar
  115. 115.
    Wickes AD and Howell SB: Pharmacokinetics of hexamethylmelamine administered via the IP route in an oil emulsion vehicle. Cancer Treat Rep 69:657–662, 1985.PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1987

Authors and Affiliations

  • Maurie Markman
  • Stephen B. Howell

There are no affiliations available

Personalised recommendations